Ribometrix snags $7.8 mln

Durham, North Carolina-based Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, has secured $7.8 million in funding. The backers are Dementia Discovery Fund and Illumina Ventures. In addition to the funding, Ribometrix has named Dr. Mike Clayman as chairman of the board of directors.

North AmericaUSBriefs